NeuroPace to Present at the 41st Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.
Related news for (NPCE)
- NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
- NeuroPace Provides Update on Tariff Status
- NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
- NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
- NeuroPace Announces Refocusing of Product Portfolio